Sanofi– tag –
-
Breakthrough: EU Approves Oral BTK Inhibitor Tolebrutinib as First Disability-Targeting Therapy for Nonrelapsing SPMS
NeurologyLive Europe Overview The European Commission has approved Sanofi's oral, brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib (Cenrifki), for nonrelapsing secondary progressive multiple sclerosis (SPMS). This a... -
Sanofi Unveils ‘Dual-Targeting Library 2.0’ to Accelerate Novel Bispecific Therapeutic Design
Sanofi France Overview Sanofi has announced its innovative 'Dual-Targeting Library (DTL) 2.0' approach for designing novel bispecific therapeutics. This strategy combines monospecific antibodies and nanobodies to build extensive bispecif... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience
Drugs.com USA Overview The U.S. FDA has approved Sanofi's subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), for multiple myeloma, significantly improving administration convenience for patients. This new formulation reduces tr... -
Owkin and Sanofi Partner to Co-Develop Next-Generation AI Agents as Part of K Pro Collaboration
Business Wire France Overview Owkin announced a multi-year K Pro collaboration with Sanofi to co-develop next-generation biopharmaceutical AI agents. This partnership builds on their strategic alliance since 2021, focusing on target iden... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr...
1